GeneDx Holdings press release ( WGS ): Q4 Non-GAAP EPS of $0.18 beats by $0.06 . Revenue of $121M (+27.0% Y/Y) beats by $0.56M . For full year 2026 management expects GeneDx to deliver: Metric Guidance Revenue $540 to $555 million vs $542.99M consensus Growth in exome and genome revenue 33% to 35% Growth in exome and genome volume 33% to 35% Adjusted gross margin At least 70% Adjusted net income P...
GeneDx Holdings press release ( WGS ): Q4 Non-GAAP EPS of $0.18 beats by $0.06 . Revenue of $121M (+27.0% Y/Y) beats by $0.56M . For full year 2026 management expects GeneDx to deliver: Metric Guidance Revenue $540 to $555 million vs $542.99M consensus Growth in exome and genome revenue 33% to 35% Growth in exome and genome volume 33% to 35% Adjusted gross margin At least 70% Adjusted net income Positive Click to enlarge Shares +7% PM. More on GeneDx Holdings GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum GeneDx Holdings Corp. Q4 2025 Earnings Preview GeneDx falls after reporting Q4 and FY25 revenue
Inovio Pharmaceuticals (NASDAQ: INO) isn't a particularly well-known or prominent name in the biotech industry, but some may remember it as one of those smaller companies that sought to develop and market a coronavirus vaccine in the early years of the pandemic. Inovio's efforts were unsuccessful, and since then, the stock has lost significant market value. Will it continue moving in the wrong dir...
Inovio Pharmaceuticals (NASDAQ: INO) isn't a particularly well-known or prominent name in the biotech industry, but some may remember it as one of those smaller companies that sought to develop and market a coronavirus vaccine in the early years of the pandemic. Inovio's efforts were unsuccessful, and since then, the stock has lost significant market value. Will it continue moving in the wrong direction? Or is there a rebound in the cards? Image source: Getty Images. First, for the good news. Inovio Pharmaceuticals is a fairly innovative company that develops DNA medicine, a type of therapy that gives patients' bodies the blueprint to produce specific immune responses to fight diseases. One of Inovio's most advanced candidates is INO-3107, a potential medicine against recurrent respiratory papillomatosis (RRP), a rare disease caused by certain strains of the HPV virus that leads to the growth of non-cancerous tumors in the respiratory tract, potentially causing severe difficulty breathing. Continue reading
“This 10% or 15%, it’s not done,” says Peter Tchir, head of macro strategy at Academy Securities, as he explains his market fears related to the Supreme Court striking down President Donald Trump’s global tariffs. (Source: Bloomberg)
“This 10% or 15%, it’s not done,” says Peter Tchir, head of macro strategy at Academy Securities, as he explains his market fears related to the Supreme Court striking down President Donald Trump’s global tariffs. (Source: Bloomberg)
Easterly Government press release ( DEA ): Q4 FFO of $0.77 in-line. Revenue of $87.04M (+11.2% Y/Y) misses by $0.69M . FY26 FFO consensus of $3.09 The Company is maintaining its guidance for full-year 2026 Core FFO per share on a fully diluted basis at a range of $3.05 - $3.12. Low High Net income (loss) per share – fully diluted basis $ 0.35 0.42 Plus: Company’s share of real estate depreciation ...
Easterly Government press release ( DEA ): Q4 FFO of $0.77 in-line. Revenue of $87.04M (+11.2% Y/Y) misses by $0.69M . FY26 FFO consensus of $3.09 The Company is maintaining its guidance for full-year 2026 Core FFO per share on a fully diluted basis at a range of $3.05 - $3.12. Low High Net income (loss) per share – fully diluted basis $ 0.35 0.42 Plus: Company’s share of real estate depreciation and amortization $ 2.68 2.68 FFO per share – fully diluted basis $ 3.03 3.10 Plus: Company’s share of depreciation of non-real estate assets $ 0.02 0.0 Click to enlarge More on Easterly Government Easterly Government Properties: An Upgrade Betting On Portfolio Growth, Despite Federal Budget Showdown Easterly Government Properties: Get Paid An 8% Yield While You Wait For The Stock To Rerate Seeking Alpha’s Quant Rating on Easterly Government Historical earnings data for Easterly Government Dividend scorecard for Easterly Government
Freshpet press release ( FRPT ): Q4 GAAP EPS of $0.64 beats by $0.25 . Revenue of $285.2M (+8.6% Y/Y) misses by $0.52M . The increase in net sales was primarily driven by volume gains of 9.7%, partially offset by unfavorable price/mix of 1.1%. For full year 2026, the Company is providing the following guidance: Net sales growth in the range of 7% to 10% compared to 2025; vs 9.39% consensus Adjuste...
Freshpet press release ( FRPT ): Q4 GAAP EPS of $0.64 beats by $0.25 . Revenue of $285.2M (+8.6% Y/Y) misses by $0.52M . The increase in net sales was primarily driven by volume gains of 9.7%, partially offset by unfavorable price/mix of 1.1%. For full year 2026, the Company is providing the following guidance: Net sales growth in the range of 7% to 10% compared to 2025; vs 9.39% consensus Adjusted EBITDA in the range of $205 million to $215 million; and Positive free cash flow with capital expenditures of ~$150 million. More on Freshpet Freshpet Looks Better Now Than It Ever Has Before (Upgrade) Freshpet, Inc. (FRPT) Presents at Morgan Stanley Global Consumer & Retail Conference 2025 Transcript Freshpet Is Still Too Expensive With Slowing Growth Freshpet Q4 2025 Earnings Preview Freshpet earns a clean label award that could justify its premium positioning
Dutchman steps down for personal reasons Caribbean island only has population of 150,000 Dick Advocaat led Curaçao to their first World Cup but will not be charge of the team at the tournament itself after resigning from the head coach’s post for personal reasons. It is believed Advocaat had stood down because of his daughter’s health. “I’ve always said family is above football. So this is a self-...
Dutchman steps down for personal reasons Caribbean island only has population of 150,000 Dick Advocaat led Curaçao to their first World Cup but will not be charge of the team at the tournament itself after resigning from the head coach’s post for personal reasons. It is believed Advocaat had stood down because of his daughter’s health. “I’ve always said family is above football. So this is a self-evident decision,” the 78-year-old is reported as saying. “But of course that doesn’t change the fact that I’m going to miss Curaçao, the people there and my colleagues very much.” Continue reading...
Anthony Albanese writes to British PM as UK prepares to consider laws to strip former prince of his right to inherit the throne Get our breaking news email , free app or daily news podcast The Australian government has confirmed it would support any proposal to remove Andrew Mountbatten-Windsor from the royal line of succession after the former prince was arrested on suspicion of misconduct in pub...
Anthony Albanese writes to British PM as UK prepares to consider laws to strip former prince of his right to inherit the throne Get our breaking news email , free app or daily news podcast The Australian government has confirmed it would support any proposal to remove Andrew Mountbatten-Windsor from the royal line of succession after the former prince was arrested on suspicion of misconduct in public office. With the UK government poised to consider laws to strip Mountbatten-Windsor of his right to inherit the throne once any policy investigation was finalised, the Australian prime minister, Anthony Albanese, has written to his British counterpart, Keir Starmer, to offer the country’s backing. Continue reading...
Report into ‘unprecedented’ violence between members of two communities in 2022 calls for action on communalism UK politics live – latest updates Violence between Hindus and Muslims in Leicester in 2022 was fuelled by online disinformation and met with a failure of leadership from the city’s mayor, council and police, an independent inquiry has said. Researchers from the School of Oriental and Afr...
Report into ‘unprecedented’ violence between members of two communities in 2022 calls for action on communalism UK politics live – latest updates Violence between Hindus and Muslims in Leicester in 2022 was fuelled by online disinformation and met with a failure of leadership from the city’s mayor, council and police, an independent inquiry has said. Researchers from the School of Oriental and African Studies and the London School of Economics carried out the study after the unrest between predominantly young Hindu and Muslim men in Leicester between May and September 2022. No single group was solely responsible, with members of Hindu and Muslim communities described as “both victims and perpetrators”. Online disinformation was a “central accelerant of the crisis”, fuelling distrust. Community coexistence in Leicester is “increasingly fragmenting” amid new migration patterns, economic decline and the importation of political ideologies such as communalism, Hindutva and political Islamism. Communalism within south Asian communities in the UK “needs to be urgently recognised and addressed”. The response from local authorities, including the city council, mayor and police was “lacking or inconsistent” with “major gaps” in intelligence and communication. Continue reading...
More on Gilead Sciences, Arcellx Time To Take Profits On Gilead Sciences (Rating Downgrade) Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript Gilead Sciences, Inc. 2025 Q4 - Results - Earnings Call Presentation Gilead in up to $1.5B deal with China's Genhouse Bio for tumor candidate Earnings Scorecard: Healthcare sector shows strong top-line pulse
More on Gilead Sciences, Arcellx Time To Take Profits On Gilead Sciences (Rating Downgrade) Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript Gilead Sciences, Inc. 2025 Q4 - Results - Earnings Call Presentation Gilead in up to $1.5B deal with China's Genhouse Bio for tumor candidate Earnings Scorecard: Healthcare sector shows strong top-line pulse
Recognizing Failure, Some Liberals Are Reshaping Their Climate Messaging Authored by Gary Abernathy via The Empowerment Alliance , Did the far left ever really believe its own rhetoric when it came to climate change? True, when it comes to the positions staked out by any politician on the issues of the day, the age-old question is constantly in the back of everyone’s minds: How much of what they c...
Recognizing Failure, Some Liberals Are Reshaping Their Climate Messaging Authored by Gary Abernathy via The Empowerment Alliance , Did the far left ever really believe its own rhetoric when it came to climate change? True, when it comes to the positions staked out by any politician on the issues of the day, the age-old question is constantly in the back of everyone’s minds: How much of what they claim to believe is based on heartfelt, core convictions, and how much is due to outside political pressure or geared toward generating contributions? But nowhere is this question more pertinent than when it comes to politicians and their advocacy for climate change. Why? Because it’s difficult to think of anything that comes close to rivaling the number of government mandates implemented and the amount of taxpayer dollars allocated to reshape society as has happened in the name of climate change. Surely, it wasn’t all based on empty rhetoric and misdirection, was it? Far-left environmental and climate change groups have significantly increased their political spending over the years. In turn, election after election features liberal politicians hammering away on the alleged damage done by the fossil fuel industry. In 2024 they were at it again, highlighting the latest scary predictions about the worst-case climate change scenarios, and fervently warning of the untold horrors that would happen if Donald Trump and Republicans won in 2024. Guess what? Once more, it all fell flat with most voters. Trump won the presidency, Republicans kept control of both the House and Senate, and across the nation GOP dominance continued in state government. There are some Democrats who finally seem to be getting the message that their climate narrative is not resonating. A recent story in Politico noted, “Democrats are increasingly showing they have decided it’s a losing message to tout the ways in which they’d curb fossil fuel production to thwart the most dire effects of climate change.” Ap...
Justin Sullivan/Getty Images News Gilead Sciences ( GILD ) has agreed to acquire biotechnology company Arcellx ( ACLX ) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an implied equity value of $7.8B payable at closing. The transaction was approved by both the Gilead and Arcellx boards of directors and is anticipated to close during the...
Justin Sullivan/Getty Images News Gilead Sciences ( GILD ) has agreed to acquire biotechnology company Arcellx ( ACLX ) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an implied equity value of $7.8B payable at closing. The transaction was approved by both the Gilead and Arcellx boards of directors and is anticipated to close during the second quarter of 2026. Arcellx is developing a new class of innovative immunotherapies for patients with cancer and other incurable diseases. Kite, a Gilead ( GILD ) company, and Arcellx have an existing collaboration to co-develop and co-commercialize Arcellx’s lead pipeline candidate, anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for patients with multiple myeloma. Shares of Arcellx ( ACLX ) jumped 77.7% premarket following the announcement. Under the merger agreement, a wholly owned Gilead subsidiary will launch a tender offer to buy all Arcellx shares it does not already own for $115 per share in cash, a 68% premium to Arcellx’s 30-day average price as of February 20, 2026. Gilead currently owns around 11.5% of Arcellx’s outstanding common stock. Shareholders will also receive one non-transferable CVR per share, which could pay an additional $5 if anito-cel achieves at least $6B in cumulative global net sales from launch through the end of 2029. If the tender offer is completed, Gilead will acquire any remaining Arcellx shares through a second-step merger on the same terms. Upon FDA approval of anito-cel, the proposed transaction is expected to be accretive to earnings per share in 2028 and thereafter. The BLA for anito-cel as a fourth-line treatment for patients with relapsed or refractory multiple myeloma is supported by results from the Phase 1 study (NCT04155749) and the pivotal Phase 2 iMMagine1 study (NCT05396885) and has been accepted by the U.S. Food and Drug Administration with an anticipated Prescription Drug User...